Last reviewed · How we verify
ibandronate, calcium and vitamin D
Ibandronate inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase, while calcium and vitamin D support bone mineralization and calcium homeostasis.
Ibandronate inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase, while calcium and vitamin D support bone mineralization and calcium homeostasis. Used for Osteoporosis prevention and treatment in postmenopausal women, Bone loss associated with glucocorticoid therapy.
At a glance
| Generic name | ibandronate, calcium and vitamin D |
|---|---|
| Sponsor | Charite University, Berlin, Germany |
| Drug class | Bisphosphonate combination therapy |
| Target | Farnesyl pyrophosphate synthase (ibandronate); calcium-sensing receptor and vitamin D receptor (supportive agents) |
| Modality | Small molecule |
| Therapeutic area | Bone metabolism / Osteoporosis |
| Phase | FDA-approved |
Mechanism of action
Ibandronate is a nitrogen-containing bisphosphonate that reduces bone turnover by inhibiting osteoclast activity and promoting osteoclast apoptosis. Calcium provides the mineral substrate for bone formation, and vitamin D enhances intestinal calcium absorption and regulates calcium-phosphate metabolism, together reducing fracture risk in osteoporosis.
Approved indications
- Osteoporosis prevention and treatment in postmenopausal women
- Bone loss associated with glucocorticoid therapy
Common side effects
- Gastrointestinal upset (nausea, dyspepsia)
- Musculoskeletal pain
- Headache
- Osteonecrosis of the jaw (rare)
- Atypical femoral fractures (rare)
Key clinical trials
- Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (NA)
- Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without Ibandronate (PHASE2)
- Efficacy and Safety of Oral Ibandronate in Patients of Liver Cirrhosis With Hepatic Osteodystrophy. (NA)
- Use of Ibandronate in Diabetic Patients (NA)
- Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients (PHASE3)
- MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis (PHASE3)
- A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate) (PHASE4)
- PTH & Ibandronate Combination Study (PICS) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: